Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis

Figure 9

Illustrative results of detecting anti-Leishmania antibodies in sera and blood for VL diagnosis using the DTL-4-based ICT. (a) Sera samples from five VL different patients were included in this assay as a positive control (visible test and control line). (b) Sera samples from negative donors for LV with a previous diagnosis (ten samples of each disease) of Chagas’ disease (CHA), malaria (MA), rheumatoid factor (RF), tegumentary leishmaniasis (TL), and healthy donor (HD) were tested. These assays presented negative results (only the control line was visible). (c) Representative test on the cassette. The sera sample from the VL patient was applied, and the control and test lines were visible.

(a)

(b)

(c)